Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.55 |
| ▸ | JAK1 | P23458 | 14/20 | 0.55 |
| ▸ | JAK3 | P52333 | 5/20 | 0.53 |
| ▸ | RET | P07949 | 3/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.53 |
| ▸ | TYK2 | P29597 | 3/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.53 |
| ▸ | PAK4 | O96013 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | LTK | P29376 | 2/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.53 |
| ▸ | CLK2 | P49760 | 2/20 | 0.53 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.53 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.53 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.53 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084638 | 0.89 | TYRO3 (0.57) | JAK2JAK1JAK3RETROCK1 | |
| SCHEMBL1498853 | 0.88 | JAK2 (0.48) | JAK2JAK1JAK3RETROCK1 | |
| SCHEMBL1498840 | 0.86 | JAK2 (0.61) | JAK2JAK1JAK3RETROCK1 | |
| SCHEMBL101072 | 0.84 | JAK2 (0.70) | JAK2JAK1JAK3RETROCK1 | |
| SCHEMBL101686 | 0.84 | JAK2 (0.70) | JAK2JAK1JAK3RETROCK1 | |
| SCHEMBL100966 | 0.84 | JAK2 (0.70) | JAK2JAK1JAK3RETROCK1 | |
| SCHEMBL2085646 | 0.81 | JAK2 (0.47) | JAK2JAK1JAK3RETROCK1 | |
| SCHEMBL1498831 | 0.81 | TYRO3 (0.47) | JAK2JAK1JAK3RETROCK1 | |
| SCHEMBL1498869 | 0.80 | JAK2 (0.48) | JAK2JAK1JAK3RETROCK1 | |
| SCHEMBL2396326 | 0.79 | JAK2 (0.77) | JAK2JAK1JAK3RETROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | claimed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | claimed |
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| WO-2011028685-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.